Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Employer
- Medical Research Council
- ;
- University of Oxford
- Cardiff University
- University of Exeter
- ; University of East Anglia
- University of London
- University of Bristol
- ; The Francis Crick Institute
- Imperial College London
- King's College London
- Nature Careers
- University of Cambridge
- ; Cardiff University
- ; Imperial College London
- ; MRC Laboratory of Medical Sciences
- ; Technical University of Denmark
- ; Université Paris 1 Panthéon-Sorbonne
- KINGS COLLEGE LONDON
- NATA
- QUEENS UNIVERSITY BELFAST
- Queen's University Belfast
- St George's University of London
- The University of Southampton
- UNIVERSITY OF SOUTHAMPTON
- University of Aberdeen
- University of Leeds
- University of Worcester
- 18 more »
- « less
-
Field
-
Medical Research Council Lifecourse Epidemiology Unit Location: Southampton General Hospital Salary: £34,980 to £42,978 Full Time Fixed Term until 30/09/2025 Closing Date: Monday 20 May 2024
-
About the job: The postholder will deliver the exciting project funded by UK Medical Research Council which involves process development of extracellular vesicles-based therapy manufacturing as
-
laboratory is multidisciplinary and international, with sustained high-quality productivity. Our work is generously supported by funding from the Medical Research Council, and an ERC Advanced Grant to the PI
-
practice, policy or regulations. The NC3Rs has an annual budget of approximately £10.5M and is primarily funded by Government through the Medical Research Council (MRC) and Biotechnology and Biological
-
, infections, and neurodegenerative diseases. An independent organisation, its founding partners are the Medical Research Council, Cancer Research UK, Wellcome, UCL, Imperial College London and King’s College
-
of approximately £10.5M and is primarily funded by Government through the Medical Research Council (MRC) and Biotechnology and Biological Sciences Research Council (BBSRC), which in turn are part of UK Research and
-
Accelerator The Medical Research Council (MRC), as part of UK Research and Innovation (UKRI), have invested a total of £30m over 4 years through the Strategic Priorities Fund to establish a nucleic acid therapy
-
neurodegenerative diseases. An independent organisation, its founding partners are the Medical Research Council (MRC), Cancer Research UK, Wellcome, UCL (University College London), Imperial College London and King’s
-
Nucleic Acid Therapy Accelerator The Medical Research Council (MRC), as part of UK Research and Innovation (UKRI), have invested a total of £30m over 4 years through the Strategic Priorities Fund
-
such as cancer, heart disease, stroke, infections, and neurodegenerative diseases. An independent organisation, its founding partners are the Medical Research Council (MRC), Cancer Research UK, Wellcome